Advances in Disease Modifying Therapies for Parkinson's Disease
Authors:
- Kambiz HassanzadehKHKambiz Hassanzadeh
- M. Maral MouradianMMM. Maral Mouradian
- 1 August 2025
- book chapter
- Published by Wiley
- p. 17-66
Abstract
No abstract availableThis publication has 182 references indexed in Scilit:
- Effect of Urate-Elevating Inosine on Early Parkinson Disease ProgressionJAMA, 2021
- Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson DiseaseJAMA Neurology, 2021
- Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene MutationsJAMA Neurology, 2020
- Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson DiseaseJAMA Neurology, 2020
- Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson DiseaseJAMA Neurology, 2019
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson DiseaseJAMA Neurology, 2018
- Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodiesAnnals of Clinical and Translational Neurology, 2016
- A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson DiseaseJAMA Neurology, 2014
- α-Synuclein Gene Rearrangements in Dominantly Inherited ParkinsonismArchives of Neurology, 2009
- Genomic investigation of α‐synuclein multiplication and parkinsonismAnnals of Neurology, 2008